Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Olezarsen (Primary)
- Indications Hyperlipoproteinaemia type I
- Focus Registrational; Therapeutic Use
- Acronyms BALANCE
- Sponsors Ionis Pharmaceuticals
- 17 Nov 2023 Status changed from active, no longer recruiting to completed.
- 04 Oct 2023 According to an Ionis Pharmaceuticals media release, company is planning to file U.S. and EU regulatory applications in early 2024.
- 26 Sep 2023 According to Ionis Pharmaceuticals Media Release, Ionis to host webcast today at 11 a.m. ET to discuss results from this study